| ReferencesReferencesg="UTF-8"?>
Key points
g class="boldFont">Screening for prostate cancer has been widely promotedg> since the early 1990s despite the lack of evidence of its efficacy.
g class="boldFont">The US Preventive Services Task Force recommended against PSA screeningg> because there is sufficient evidence that the harms of screening outweigh its benefits.
Yet more than g class="boldFont">half of French doctors are in favor of screeningg> and the use of PSA assays continue to grow, by 4.6%between 2009 and 2010.
The sale of a g class="boldFont">rapid immunological test for PSAg>, intended for home use, can only aggravate a situation already out of control.
g class="boldFont">The role of the French authoritiesg> in the present situation cannot be ignored.